`
`First Named Inventor: Dennis Mark MCDAID|Confirmation No.: 5282
`
`Applicant: XEOLAS PHARMACEUTICALS$|Art Unit: Zo Be Assigned
`LTD.
`
`Application No.: 18/182,797
`
`Examiner: 7o Be Assigned
`
`Filing Date: March 13, 2023
`
`Atty. Docket: 4384.0010005
`
`Title: PEDIATRIC SUSPENSION FORMULATION
`
`Second Supplemental Information Disclosure Statement
`
`Mail Stop Amendment
`
`Commissionerfor Patents
`PO Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Listed on the accompanying form equivalent to forms PTO/SB/08a and PTO/SB/08b is a
`
`document that may be considered material to the patentability of this application as defined in 37
`
`C.F.R. § 1.56. The documentis being filed in compliance with the duty of disclosure requirements of
`
`37 C.F.R. §§ 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure
`
`Statement
`
`is a continuation of the numbering in Applicant's First Supplemental Information
`
`Disclosure Statementfiled on April 29, 2024.
`
`Applicant haslisted the publication date on the attached form based on information presently
`
`available to the undersigned. However, the listed publication date should not be construed as an
`
`admission that the information wasactually published on the date indicated.
`
`
`
`-2-
`
`Dennis Mark MCDAID
`Application No.: 18/182,797
`
`Applicant reserves the right to establish the patentability of the claimed invention over any of
`
`the information provided herewith, and/or to prove that this information may notbe priorart, and/or
`
`to prove that this information may not be enabling for the teachings purportedly offered.
`
`This statement should not be construed as a representation that a search has been made,orthat
`
`information more material to the examination of the present patent application does not exist. The
`
`Examineris specifically requested not to rely solely on the material submitted herewith.
`
`Filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statementis being filed before
`
`the mailing date ofa first Office Action on the merits. No statementor fee is required.
`
`A copy of document FP10 is submitted.
`
`It is respectfully requested that the Examinerinitial and return a copy of the attached IDS
`
`Form, and indicate in the official file wrapper of this patent application that the document has been
`
`considered. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency,
`
`or credit any overpayment, to our Deposit Account No. 19-0036.
`
`July 10, 2024
`Date:
`1101 K Street, NW, 10" Floor
`Washington, D.C. 20005
`Main: 202-371-2600
`Direct: 202-772-8787
`
`Respectfully submitted,
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`/Matthew S. Bodenstein/
`
`Matthew S. Bodenstein
`Attorney for Applicant
`Registration No. 58,885
`
`22697553.1
`
`Atty. Dkt. No. 4384.0010005
`
`